YU36199A - Vodene suspenzije za nazalnu primenu - Google Patents
Vodene suspenzije za nazalnu primenuInfo
- Publication number
- YU36199A YU36199A YU36199A YU36199A YU36199A YU 36199 A YU36199 A YU 36199A YU 36199 A YU36199 A YU 36199A YU 36199 A YU36199 A YU 36199A YU 36199 A YU36199 A YU 36199A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- aqueous suspension
- suspension
- nasal administration
- loteprednol etabonate
- dermal
- Prior art date
Links
- 239000007900 aqueous suspension Substances 0.000 title abstract 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 abstract 2
- 229960003744 loteprednol etabonate Drugs 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 231100000017 mucous membrane irritation Toxicity 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
Za loteprednol etabonat koji ima izvanredne antiimflamatorske i antialergijske aktivnosti se očekuje da bude razvijen kao lek za spoljnu primenu ali kada je formulisan u vodenoj suspenziji, dovodi do agregacije i precipitacije čestica. Prema ovom pronalasku, dugotrajna stabilizacija suspenzija se uspešno postiže sa formulisanjem loteprednol etabonata sa mikrokristalima celuloze karameloze natrijuma. Još više, rezultujuća suspenzija pokazuje značajno poboljšanje intranazalne retencije i odsustvo dermalne ili sluzne iritacije.[Loteprednol etabonate having excellent antiinflammatory and antiallergic activities is expected to be developed as a drug for external application but when it is formulated into an aqueous suspension, the aggregation and precipitation of particles tend to take place. According to the present invention, long-term stabilization of the suspension was successfully achieved by formulating loteprednol etabonate with microcrystalline cellulose carmellose sodium. Moreover, the resulting suspension features a remarkably improved intranasal retention and no dermal or mucosal irritation.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1966497 | 1997-01-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU36199A true YU36199A (sh) | 2002-09-19 |
| RS49701B RS49701B (sr) | 2007-12-31 |
Family
ID=12005518
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6368616B1 (sh) |
| EP (1) | EP0973501B1 (sh) |
| KR (1) | KR100471708B1 (sh) |
| CN (1) | CN1126535C (sh) |
| AR (1) | AR011773A1 (sh) |
| AT (1) | ATE249205T1 (sh) |
| AU (1) | AU730953C (sh) |
| BR (1) | BR9806771A (sh) |
| CA (1) | CA2278025C (sh) |
| CZ (1) | CZ294919B6 (sh) |
| DE (1) | DE69818026T2 (sh) |
| DK (1) | DK0973501T3 (sh) |
| EA (1) | EA001775B1 (sh) |
| ES (1) | ES2206880T3 (sh) |
| HU (1) | HU226613B1 (sh) |
| ID (1) | ID21892A (sh) |
| IL (1) | IL130979A0 (sh) |
| LT (1) | LT4677B (sh) |
| LV (1) | LV12449B (sh) |
| MX (1) | MXPA99006628A (sh) |
| NO (1) | NO324619B1 (sh) |
| NZ (2) | NZ336990A (sh) |
| PL (1) | PL190753B1 (sh) |
| PT (1) | PT973501E (sh) |
| RS (1) | RS49701B (sh) |
| SI (1) | SI20057A (sh) |
| SK (1) | SK283164B6 (sh) |
| TR (1) | TR199901663T2 (sh) |
| TW (1) | TW503113B (sh) |
| UA (1) | UA52722C2 (sh) |
| WO (1) | WO1998031343A2 (sh) |
| ZA (1) | ZA98303B (sh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243687B (en) | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| AU762145C (en) | 1998-08-26 | 2005-03-17 | Teijin Limited | Powdery pernasal compositions |
| DE19947235A1 (de) * | 1999-09-30 | 2001-04-05 | Asta Medica Ag | Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten |
| AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| US6565832B1 (en) * | 2000-01-31 | 2003-05-20 | Schering-Plough Healthcare Products, Inc. | Spray composition with reduced dripping |
| AU2002320038B2 (en) * | 2001-06-18 | 2007-07-05 | Noven Pharmaceuticals, Inc. | Enhanced drug delivery in transdermal systems |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| DE602004008083T2 (de) * | 2003-06-19 | 2008-04-24 | Nicholas S. Gainsville Bodor | Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden |
| EP1653974B1 (en) | 2003-06-19 | 2010-01-06 | BODOR, Nicholas S. | Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application |
| US20050095205A1 (en) * | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
| DE602005016392D1 (de) | 2004-03-25 | 2009-10-15 | Bausch & Lomb | Verwendung von loteprednoletabonat zur behanldung von trockenen augen |
| US20070099883A1 (en) * | 2005-10-07 | 2007-05-03 | Cheryl Lynn Calis | Anhydrous mometasone furoate formulation |
| WO2007058935A2 (en) * | 2005-11-14 | 2007-05-24 | Bausch & Lomb Incorporated | Ophthalmic composition for dry eye therapy |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| US7687484B2 (en) * | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
| WO2012119261A1 (en) * | 2011-03-10 | 2012-09-13 | Biocia Inc. | Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis |
| WO2013043387A1 (en) | 2011-09-22 | 2013-03-28 | Bausch & Lomb Incorporated | Ophthalmic gel compositions |
| RS65380B1 (sr) | 2017-08-24 | 2024-04-30 | Novo Nordisk As | Glp-1 kompozicije i njihova upotreba |
| IL294520A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | Pharmaceutical formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| EP0709099A3 (en) | 1994-09-28 | 1996-07-24 | Senju Pharma Co | Aqueous suspension for nasal administration containing cyclodextrin |
| KR100508227B1 (ko) | 1997-03-14 | 2006-03-23 | 센주 세이야꾸 가부시키가이샤 | 로테프레드놀에타보네이트수성현탁액 |
-
1998
- 1998-01-06 TW TW087100103A patent/TW503113B/zh not_active IP Right Cessation
- 1998-01-14 DK DK98900360T patent/DK0973501T3/da active
- 1998-01-14 ID IDW990725A patent/ID21892A/id unknown
- 1998-01-14 MX MXPA99006628A patent/MXPA99006628A/es not_active IP Right Cessation
- 1998-01-14 AU AU54952/98A patent/AU730953C/en not_active Ceased
- 1998-01-14 NZ NZ336990A patent/NZ336990A/xx unknown
- 1998-01-14 IL IL13097998A patent/IL130979A0/xx not_active IP Right Cessation
- 1998-01-14 AT AT98900360T patent/ATE249205T1/de not_active IP Right Cessation
- 1998-01-14 CA CA002278025A patent/CA2278025C/en not_active Expired - Fee Related
- 1998-01-14 RS YUP-361/99A patent/RS49701B/sr unknown
- 1998-01-14 TR TR1999/01663T patent/TR199901663T2/xx unknown
- 1998-01-14 CZ CZ19992374A patent/CZ294919B6/cs not_active IP Right Cessation
- 1998-01-14 KR KR10-1999-7006440A patent/KR100471708B1/ko not_active Expired - Fee Related
- 1998-01-14 ES ES98900360T patent/ES2206880T3/es not_active Expired - Lifetime
- 1998-01-14 BR BR9806771-0A patent/BR9806771A/pt not_active IP Right Cessation
- 1998-01-14 US US09/341,522 patent/US6368616B1/en not_active Expired - Fee Related
- 1998-01-14 PT PT98900360T patent/PT973501E/pt unknown
- 1998-01-14 DE DE69818026T patent/DE69818026T2/de not_active Expired - Fee Related
- 1998-01-14 PL PL334614A patent/PL190753B1/pl not_active IP Right Cessation
- 1998-01-14 EA EA199900659A patent/EA001775B1/ru not_active IP Right Cessation
- 1998-01-14 WO PCT/JP1998/000108 patent/WO1998031343A2/en active IP Right Grant
- 1998-01-14 SK SK948-99A patent/SK283164B6/sk not_active IP Right Cessation
- 1998-01-14 HU HU0002473A patent/HU226613B1/hu not_active IP Right Cessation
- 1998-01-14 UA UA99084658A patent/UA52722C2/uk unknown
- 1998-01-14 CN CN98803402A patent/CN1126535C/zh not_active Expired - Fee Related
- 1998-01-14 NZ NZ509908A patent/NZ509908A/xx unknown
- 1998-01-14 SI SI9820018A patent/SI20057A/sl not_active IP Right Cessation
- 1998-01-14 EP EP98900360A patent/EP0973501B1/en not_active Expired - Lifetime
- 1998-01-14 ZA ZA98303A patent/ZA98303B/xx unknown
- 1998-01-16 AR ARP980100191A patent/AR011773A1/es active IP Right Grant
-
1999
- 1999-07-13 NO NO19993453A patent/NO324619B1/no not_active IP Right Cessation
- 1999-07-15 LV LVP-99-109A patent/LV12449B/en unknown
- 1999-08-12 LT LT99-100A patent/LT4677B/lt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU36199A (sh) | Vodene suspenzije za nazalnu primenu | |
| GB0105772D0 (en) | Use | |
| IL121565A0 (en) | Pharmaceutical composition stabilized with a basic agent | |
| CA2177524A1 (en) | Nasal mask | |
| EP1057494A3 (en) | Air mask with seal | |
| AU2878689A (en) | Locally administrable 2-amino-3-benzoyl phenylacetic acid derivatives as therapeutic compositions for inflammatory disease | |
| MXPA03006439A (es) | Metodo y composiciones novedosos para tratamiento local del mal del meniere, zumbido de oidos y/o perdida de oido. | |
| NZ510887A (en) | Formulations of fexofenadine for ocular and nasal delivery | |
| PL357132A1 (en) | Stable, nasally, orally or sublingually applicable pharmaceutical preparation | |
| PL347171A1 (en) | Insulin preparations for pulmonary delivery containing menthol | |
| IS6654A (is) | Stöðugt gabapentín með pH innan stýrðra marka | |
| ATE254851T1 (de) | Iod-herstellungszusammensetzung | |
| CA2411582A1 (en) | Method for increasing the antioxidative potential of selenium-containing aqueous solutions | |
| ES2052977T3 (es) | Composicion que contiene bismuto. | |
| AU9530798A (en) | Tracheotomy cannula with shield | |
| CN204275235U (zh) | Cpap鼻面罩固定组件 | |
| CA2270004A1 (en) | Stable mitoxantrone solutions | |
| ATE203903T1 (de) | Delta-aminolävulinsäure enthaltendes arzneimittel | |
| AU2002311412A1 (en) | Thickened aqueous compositions | |
| HUT75939A (en) | Intranasal composition containing active ingredient having antimigraine effect and chitosan | |
| CN213123740U (zh) | 一种反扣式义甲固定带 | |
| CN213048776U (zh) | 一种儿童专用防脱落式鼻氧管 | |
| AU2001258859A1 (en) | Pralmorelin-containing nasal drop preparations | |
| CN215649395U (zh) | 一种贴脸式防勒耳医用口罩 | |
| AU2001292423A1 (en) | Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid |